临床局限性膀胱癌与肾癌的性别差异:发病、诊断、治疗与结局
本文综述了男性与女性在膀胱癌和肾细胞癌(RCC)发病、诊断、治疗及结局方面的差异,并总结了解释这些差异的证据。膀胱癌和RCC在男性中发病率更高,男性既往较高的吸烟率可解释部分但非全部差异,激素与遗传因素亦有贡献。膀胱癌中雄激素受体和雌激素受体β与性别及肿瘤特征相关,RCC中关系尚不明确;两者均发现男女基因突变模式差异,尤其X染色体基因。诊断与治疗差异也导致性别差异。
要点
- 膀胱癌和RCC男性发病率更高,吸烟仅部分解释差异。
- 激素受体(AR、ERβ)和X染色体基因突变模式与性别差异相关。
- 男女在诊断检查与治疗上的差异也促成性别差异。
核心结论
- 深入研究激素轴和遗传学如何导致膀胱癌与RCC发病和结局差异,将推动更个体化的医疗。
- 认识诊断和治疗障碍有助于发现改善患者照护的机会。
研究设计与样本
- 通过PubMed和Google Scholar对当前文献进行的综述。
主要发现
- 膀胱癌和RCC的发病率男性高于女性。
- 男性既往较高吸烟率解释部分但非全部发病率差异,激素和遗传因素亦有贡献。
- 膀胱癌中雄激素受体和雌激素受体β与性别及肿瘤特征相关,RCC中关系较不明确。
- 膀胱癌和RCC中均发现男女基因突变模式差异,尤其X染色体基因。
- 男女在膀胱癌和RCC的诊断检查与治疗上的差异也促成性别差异。
临床怎么用
- 临床应认识膀胱癌和RCC在发病、诊断、治疗及结局上的性别差异,以促进个体化诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review differences in bladder and renal cell cancer (RCC) incidence, diagnosis, treatment, and outcomes between men and women, and to summarize the evidence that explains these differences. METHODS: A review of the current literature was performed using PubMed and Google Scholar. RESULTS: The incidence of bladder cancer and RCC is higher in men. Historically higher smoking rates among men explain some but not all of the difference in incidence. Hormonal and genetic factors also contribute. In bladder cancer, the androgen receptor and estrogen receptor beta have been associated with gender and tumor characteristics. In RCC the relationships are less well defined. In both bladder cancer and RCC, differences in gene mutation patterns among men and women, particularly among genes located on the X-chromosome, have also been identified. Differences in the work-up and treatment of men and women with bladder cancer and RCC also contribute to gender disparities. CONCLUSION: Research to better delineate how the hormonal axis and genetics contribute to disparities in bladder cancer and RCC incidence and outcomes will allow for more individualized medicine. Appreciation of barriers to diagnosis and treatment will identify opportunities to improve patient care.
引用
- Gul ZG, Liaw CW, Mehrazin R, et al. Gender Differences in Incidence, Diagnosis, Treatments, and Outcomes in Clinically Localized Bladder and Renal Cancer. Urology. 2020. PMID: 32561364. doi:10.1016/j.urology.2020.05.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。